Liquidia (NASDAQ:LQDA) General Counsel Russell Schundler Sells 13,692 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 13,692 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $389,948.16. Following the completion of the sale, the general counsel owned 602,841 shares of the company’s stock, valued at $17,168,911.68. The trade was a 2.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Price Performance

NASDAQ LQDA opened at $26.81 on Wednesday. Liquidia Corporation has a 1 year low of $21.94 and a 1 year high of $93.61. The company has a fifty day simple moving average of $63.40 and a 200 day simple moving average of $61.76. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The company has a market cap of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business’s revenue was up 1842.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.49) EPS. On average, sell-side analysts predict that Liquidia Corporation will post 2.05 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its stake in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares during the period. Eversept Partners LP raised its holdings in Liquidia by 33.0% in the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after acquiring an additional 167,949 shares in the last quarter. Pale Fire Capital SE lifted its position in shares of Liquidia by 2.4% in the 1st quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock worth $14,657,000 after acquiring an additional 8,985 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $29,694,000. Finally, Seven Fleet Capital Management LP lifted its position in shares of Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after acquiring an additional 51,727 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently commented on LQDA. Zacks Research lowered Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Royal Bank Of Canada set a $130.00 target price on Liquidia in a research note on Friday, July 24th. Wall Street Zen lowered Liquidia from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $30.00 target price (down from $108.00) on shares of Liquidia in a report on Friday, October 2nd. Finally, Citigroup reaffirmed a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $83.69.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).